Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

K8, delivered via a sustained-release intravitreous implant, is the Company’s lead product for retinal diseases ... trial in subjects with Thyroid Eye Disease (NCT06467435).

Graves’ disease is an autoimmune condition and the most common cause of hyperthyroidism in countries with iodine sources. In this disease, B lymphocytes produce high levels of thyroid-stimulating ...

Researchers have conducted one of the largest eye studies in the world to reveal new insights into retinal thickness, highlighting its potential in the early detection of diseases like type 2 diabetes ...

Diabetic retinopathy is an eye disease that can develop in people with diabetes. Without treatment, it can lead to vision loss and blindness. Fundus photography forms part of fundoscopy ...

Modifiable risk factors for thyroid eye disease include smoking habits and patient endocrine status. Avoid treating patients with active TED with radioactive iodine ablation. KOLOA, Hawaii ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The trial achieved its primary endpoint of proptosis ...